Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas

The PD-1 inhibitor pembrolizumab (Keytruda) displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes, according to findings from the phase 2 A

Updated on: November 07,2023

Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas

The PD-1 inhibitor pembrolizumab (Keytruda) displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes, according to findings from the phase 2 A

Updated on:November 07,2023

Why new cancer treatment discoveries are proliferating

by Karen L. Brooks,University of PennsylvaniaSunil Singhal, MD, examines lung tissue during a surgical procedure using a glowing tumor agent, while a colleague observes. Credit: University of Pe

Updated on: January 08,2024

Why new cancer treatment discoveries are proliferating

by Karen L. Brooks,University of PennsylvaniaSunil Singhal, MD, examines lung tissue during a surgical procedure using a glowing tumor agent, while a colleague observes. Credit: University of Pe

Updated on:January 08,2024

Why millennials should know colon cancer symptoms

by Deb BalzerCredit: Unsplash/CC0 Public DomainMore younger adults are being diagnosed with colon cancer —also known as colorectal cancer—and at more advanced stages of the disease, says the American

Updated on: January 08,2024

Why millennials should know colon cancer symptoms

by Deb BalzerCredit: Unsplash/CC0 Public DomainMore younger adults are being diagnosed with colon cancer —also known as colorectal cancer—and at more advanced stages of the disease, says the American

Updated on:January 08,2024

Novel drug shows promising efficacy for patients with multiple myeloma

by Jenny Owen,Emory UniversityScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDResults of an international clin

Updated on: December 18,2023

Novel drug shows promising efficacy for patients with multiple myeloma

by Jenny Owen,Emory UniversityScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDResults of an international clin

Updated on:December 18,2023

Racial disparity in pro-metastatic tumor microenvironment among women with residual breast cancer after NAC

byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainResidual tumors from Black patients with estrogen receptor (ER)-positive/HER2-negative primary breast cancer treated w

Updated on: December 17,2023

Racial disparity in pro-metastatic tumor microenvironment among women with residual breast cancer after NAC

byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainResidual tumors from Black patients with estrogen receptor (ER)-positive/HER2-negative primary breast cancer treated w

Updated on:December 17,2023

Analysis of radiotherapy and locoregional recurrence in RxPONDER patients

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainAn analysis of data on the use of radiation therapy in a large clinical trial of patients with HR+, HER2- breast cancer who had one to

Updated on: December 17,2023

Analysis of radiotherapy and locoregional recurrence in RxPONDER patients

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainAn analysis of data on the use of radiation therapy in a large clinical trial of patients with HR+, HER2- breast cancer who had one to

Updated on:December 17,2023

New blood test revolutionizes early cancer detection in Li-Fraumeni Syndrome patients

In a study published inCancer Discovery, researchers from Canada tested the use of a multimodal liquid biopsy assay based on cell-free DNA (cfDNA) for early cancer detection in patients with Li-

Updated on: October 30,2023

New blood test revolutionizes early cancer detection in Li-Fraumeni Syndrome patients

In a study published inCancer Discovery, researchers from Canada tested the use of a multimodal liquid biopsy assay based on cell-free DNA (cfDNA) for early cancer detection in patients with Li-

Updated on:October 30,2023

First-in-human trial for new lung cancer immunotherapy

byCancer Research UKCancer Research UK and Vaccitech Oncology Limited (VOLT), today (Wednesday) announce a new partnership to bring a novel immunotherapeutic vaccine strategy to patients with lu

Updated on: December 22,2023

First-in-human trial for new lung cancer immunotherapy

byCancer Research UKCancer Research UK and Vaccitech Oncology Limited (VOLT), today (Wednesday) announce a new partnership to bring a novel immunotherapeutic vaccine strategy to patients with lu

Updated on:December 22,2023

Significant treatment attrition rate seen in multiple myeloma

by Elana GotkineThere is a significant treatment attrition rate in newly diagnosed multiple myeloma (NDMM), according to a study published in the November issue ofLeukemia & Lymphoma.Victor

Updated on: December 21,2023

Significant treatment attrition rate seen in multiple myeloma

by Elana GotkineThere is a significant treatment attrition rate in newly diagnosed multiple myeloma (NDMM), according to a study published in the November issue ofLeukemia & Lymphoma.Victor

Updated on:December 21,2023

Analyzing a Study on the Therapeutic Potential of Targeting IL-20RB in Lung Cancer Bone Metastasis

Updated on: September 15,2024

Analyzing a Study on the Therapeutic Potential of Targeting IL-20RB in Lung Cancer Bone Metastasis

Updated on:September 15,2024

Basic research opens up new therapeutic opportunities for fighting leukemia

byUniversity of Veterinary Medicine—ViennaGenome-wide CRISPR/Cas9-based loss-of-function screen identifies genetic dependencies of STAT3Y640F-driven cells a) Schematic illustration of a competit

Updated on: December 25,2023

Basic research opens up new therapeutic opportunities for fighting leukemia

byUniversity of Veterinary Medicine—ViennaGenome-wide CRISPR/Cas9-based loss-of-function screen identifies genetic dependencies of STAT3Y640F-driven cells a) Schematic illustration of a competit

Updated on:December 25,2023

Enfortumab Vedotin Plus Pembrolizumab Generates Survival Benefit in Previously Untreated

September 22, 2023Chris RyanTreatment with the combination of enfortumab Vedotin and pembrolizumab led to an improvement in overall survival and progression-free survival compared with chemotherapy in

Updated on: October 15,2023

Enfortumab Vedotin Plus Pembrolizumab Generates Survival Benefit in Previously Untreated

September 22, 2023Chris RyanTreatment with the combination of enfortumab Vedotin and pembrolizumab led to an improvement in overall survival and progression-free survival compared with chemotherapy in

Updated on:October 15,2023